T. Wagenaar

发表

Anti–miR-21 Suppresses Hepatocellular Carcinoma Growth via Broad Transcriptional Network Deregulation

R. Baffa, A. Pavlícek, Sung‐Min Ahn, 2015, Molecular Cancer Research.

Utility of the RIG-I Agonist Triphosphate RNA for Melanoma Therapy

K. Grandien, D. Wiederschain, Felix A Gnerlich, 2019, Molecular Cancer Therapeutics.

Vaccinia Virus Entry into Cells via a Low-pH-Dependent Endosomal Pathway

B. Moss, A. Townsley, A. Weisberg, 2006, Journal of Virology.

Identification of the authentic varicella‐zoster virus gB (gene 31) initiating methionine overlapping the 3′ end of gene 30

W. Jackson, C. Grose, L. Marešová, 2003, Journal of medical virology.

A Conserved Sequence within the H2 Subunit of the Vaccinia Virus Entry/Fusion Complex Is Important for Interaction with the A28 Subunit and Infectivity

B. Moss, T. Wagenaar, G. E. Nelson, 2008, Journal of Virology.

Wild-Type Kaposi's Sarcoma-Associated Herpesvirus Isolated from the Oropharynx of Immune-Competent Individuals Has Tropism for Cultured Oral Epithelial Cells

C. Grose, J. Webster-Cyriaque, K. Duus, 2004, Journal of Virology.

Local delivery of mRNA-encoding cytokines promotes antitumor immunity and tumor eradication across multiple preclinical tumor models

G. Nabel, D. Wiederschain, U. Şahin, 2021, Science Translational Medicine.

An experimental model of anti-PD-1 resistance exhibits activation of TGFß and Notch pathways and is sensitive to local mRNA immunotherapy

Joon Sang Lee, D. Wiederschain, J. Pollard, 2021, Oncoimmunology.

Genomic analysis of varicella-zoster virus: primers for individual open reading frames.

C. Grose, V. Loparev, J. Breuer, 2003, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

The out of Africa model of varicella-zoster virus evolution: single nucleotide polymorphisms and private alleles distinguish Asian clades from European/North American clades.

V. Chow, C. Grose, Chantanee Buranathai, 2003, Vaccine.

Regulation of infected cell fusion by the vaccinia virus A56 and K2 proteins

T. Wagenaar, 2008 .

Vaccinia Virus A56/K2 Fusion Regulatory Protein Interacts with the A16 and G9 Subunits of the Entry Fusion Complex

B. Moss, T. Wagenaar, Suany Ojeda, 2008, Journal of Virology.

Resistance to vemurafenib resulting from a novel mutation in the BRAFV600E kinase domain

Michael R. Green, Benjamin P. Roscoe, D. Bolon, 2014, Pigment cell & melanoma research.

An Open-Label, First-in-Human, Dose-Escalation Study of SAR443579 Administered As Single Agent By Intravenous Infusion in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-Cell Acute Lymphoblastic Leukemia (B-ALL) or High-Risk Myelodysplasia (HR-MDS)

M. Jongen‐Lavrencic, A. Wei, S. de Botton, 2022, Blood.

Expression of the A56 and K2 Proteins Is Sufficient To Inhibit Vaccinia Virus Entry and Cell Fusion

B. Moss, T. Wagenaar, 2008, Journal of Virology.

Association of Vaccinia Virus Fusion Regulatory Proteins with the Multicomponent Entry/Fusion Complex

B. Moss, T. Wagenaar, 2007, Journal of Virology.

Identification of the endosomal sorting complex required for transport-I (ESCRT-I) as an important modulator of anti-miR uptake by cancer cells

Madelyn Light, Q. Gao, D. Wiederschain, 2014, Nucleic acids research.

Nanobody-siRNA Conjugates for Targeted Delivery of siRNA to Cancer Cells.

K. Jahn-Hofmann, P. Casteels, M. Helms, 2021, Molecular Pharmaceutics.

Expression of the A56 and K2 Proteins Is Sufficient To Inhibit Vaccinia Virus Entry and Cell Fusion

B. Moss, T. Wagenaar, 2008, Journal of Virology.